Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat.

@article{Huang2012OrlistatAN,
  title={Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat.},
  author={Hui-Qiong Huang and Jing Tang and Shengtao Zhou and Tao Yi and Hong-ling Peng and Guo-bo Shen and Na Xie and Kai Huang and Tao Yang and Jin-hua Wu and Canhua Huang and Yu-quan Wei and Xia Zhao},
  journal={International journal of oncology},
  year={2012},
  volume={41 2},
  pages={
          523-32
        }
}
Orlistat is an orally administered anti-obesity drug that has shown significant antitumor activity in a variety of tumor cells. To identify the proteins involved in its antitumor activity, we employed a proteomic approach to reveal protein expression changes in the human ovarian cancer cell line SKOV3, following Orlistat treatment. Protein expression profiles were analyzed by 2-dimensional polyacrylamide gel electrophoresis (2-DE) and… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat

CW IVPemble, LC Johnson, SJ Kridel, WT Lowther
  • Nat Struct Mol Biol
  • 2007
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

Cancer statistics, 2008.

  • CA: a cancer journal for clinicians
  • 2008